Cargo Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
Tang Capital reports the completion of a merger with Cargo Therapeutics through Concentra Merger Sub VII, resulting in Cargo Therapeutics becoming a wholly-owned subsidiary of Concentra Biosciences.
Cargo Therapeutics, Inc. has entered into a definitive merger agreement to be acquired by Concentra Biosciences, LLC for $4.379 per share in cash plus one contingent value right.
SCHEDULE 13D: Tang Capital Group Discloses 5.9% Stake in CARGO Therapeutics, Signaling Potential Strategic Engagement
Tang Capital Management and affiliated entities have disclosed a 5.9% beneficial ownership stake in CARGO Therapeutics, Inc., acquired for investment purposes with potential for strategic discussions.